Biggest News Aggregation in the World
📰 Leukemia Unit News

Leukemia Unit News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Leukemia Unit. Real-time updates on events, politics, business and more.

European Commission Expands Approval of Bristol Myers Squibb's Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS) -April 02, 2024 at 08:09 pm EDT

Approval of Reblozyl is based on head-to-head, pivotal Phase 3 COMMANDS study, in which Reblozyl nearly doubled the percentage of patients achieving transfusion independence and hemoglobin increase,...
United Kingdom United States Bristol Myers Squibb Monica Shaw Leukemia Unit At Humanitas Cancer Center Acceleron Pharma Inc

Luspatercept-aamt Shows Efficacy Treating Anemia Due to Myelodysplastic Syndromes

Trial results demonstrated that 58.5% of individuals receiving luspatercept-aamt (Reblozyl; Bristol Myers Squibb) achieved the primary endpoint of red blood cell transfusion independence of at least 12 weeks.
United States Guillermo Garcia Manero Bristol Myers Squibb University Of Texas Md Anderson Cancer Center European Medicines Agency Leukemia Unit At Humanitas Cancer Center

Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl® (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)

Results from Phase 3 COMMANDS study, selected for ASCO’s official press program, show nearly twice as many patients treated with Reblozyl achieved superior transfusion independence with... | May 25, 2023
United States Maedica Bucur Noah Berkowitz Guillermo Garcia Manero Bristol Myers Squibb Origar Beta

Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)

Results from Phase 3 COMMANDS study, selected for ASCO's official press program, show nearly twice as many patients treated with Reblozyl achieved superior transfusion independence with concurrent
United States Bristol Myers Squibb Noah Berkowitz Origar Beta Maedica Bucur Gewinn Nur

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science